Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAR-T Funding: It's (Nearly) All About The Price In The UK

Executive Summary

Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding

Related Content

UK: Funding For Second Kymriah Indication After Talks And Price Cut
NICE Explains Its UK Funding Recommendation For Kymriah
CAR-T Therapies Should Impress EU Reimbursement Bodies
Another CAR-T First: Yescarta Wins Lymphoma Funding In England


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts